Urbain Jalenques-Tauveron

Clermont-ferrand, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 02, 2026

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

Treatment Modalities and the Impact of Granulocyte Colony-Stimulating Factor in AML Patients Treated With Venetoclax and Azacitidine: A DATAML Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 05, 2026

EASIX score is predictive of early fatal complications in newly diagnosed acute myeloid leukemia.

EASIX score is predictive of early fatal complications in newly diagnosed acute myeloid leukemia.

Journal: Annals of hematology

Published: February 03, 2026

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Hypomethylating agents plus venetoclax versus intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Journal: Haematologica

Published: November 10, 2025

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.

Journal: Leukemia

Published: October 25, 2025

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.

Journal: British journal of haematology

Published: October 02, 2025

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group.

Journal: Bone marrow transplantation

Published: October 01, 2025

Luspatercept as first line in transfusion-dependant very low to intermediate risk myelodysplastic syndromes

Luspatercept as first line in transfusion-dependant very low to intermediate risk myelodysplastic syndromes

Journal: Bulletin du cancer

Published: November 11, 2024

Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.

Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.

Journal: Annals of hematology

Published: October 12, 2024

Updates on hairy cell leukemia (HCL) and HCL-like disorders

Updates on hairy cell leukemia (HCL) and HCL-like disorders

Journal: Bulletin du cancer

Published: October 08, 2024

Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy

Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy

Journal: Bulletin du cancer

Published: December 27, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026